Wall Street brokerages forecast that HTG Molecular Diagnostics Inc (NASDAQ:HTGM) will announce earnings per share (EPS) of ($0.17) for the current quarter, Zacks reports. Two analysts have made estimates for HTG Molecular Diagnostics’ earnings. The lowest EPS estimate is ($0.24) and the highest is ($0.10). HTG Molecular Diagnostics reported earnings of ($0.15) per share during the same quarter last year, which would indicate a negative year over year growth rate of 13.3%. The firm is expected to announce its next earnings results on Thursday, March 28th.
According to Zacks, analysts expect that HTG Molecular Diagnostics will report full-year earnings of ($0.70) per share for the current year, with EPS estimates ranging from ($0.79) to ($0.63). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.50) per share, with EPS estimates ranging from ($0.57) to ($0.45). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow HTG Molecular Diagnostics.
HTG Molecular Diagnostics (NASDAQ:HTGM) last announced its earnings results on Thursday, November 8th. The medical research company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.01. The company had revenue of $4.71 million during the quarter, compared to the consensus estimate of $5.14 million. HTG Molecular Diagnostics had a negative return on equity of 132.67% and a negative net margin of 81.10%.
Several brokerages have recently weighed in on HTGM. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of HTG Molecular Diagnostics in a research note on Friday, September 28th. ValuEngine upgraded HTG Molecular Diagnostics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 27th. Cantor Fitzgerald began coverage on HTG Molecular Diagnostics in a research note on Thursday, September 20th. They set a “buy” rating and a $7.00 target price for the company. Finally, Zacks Investment Research downgraded HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 10th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. HTG Molecular Diagnostics currently has a consensus rating of “Buy” and an average target price of $6.25.
Shares of HTG Molecular Diagnostics stock traded down $0.49 during trading hours on Friday, hitting $3.65. 609,889 shares of the company’s stock traded hands, compared to its average volume of 1,010,639. The company has a debt-to-equity ratio of 0.35, a current ratio of 9.50 and a quick ratio of 9.29. The company has a market capitalization of $112.55 million, a PE ratio of -2.04 and a beta of 2.03. HTG Molecular Diagnostics has a twelve month low of $1.71 and a twelve month high of $5.83.
Several institutional investors and hedge funds have recently added to or reduced their stakes in HTGM. Northern Trust Corp bought a new stake in HTG Molecular Diagnostics during the first quarter worth approximately $189,000. BlackRock Inc. grew its holdings in shares of HTG Molecular Diagnostics by 322.8% during the 2nd quarter. BlackRock Inc. now owns 73,044 shares of the medical research company’s stock valued at $238,000 after acquiring an additional 55,769 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of HTG Molecular Diagnostics during the 2nd quarter valued at $353,000. GSA Capital Partners LLP purchased a new position in shares of HTG Molecular Diagnostics during the 2nd quarter valued at $650,000. Finally, Spark Investment Management LLC bought a new stake in HTG Molecular Diagnostics in the second quarter worth $663,000. 50.55% of the stock is currently owned by institutional investors.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.
Read More: Benefits of owning preferred stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.